HRP20251050T1 - Ciklični dinukleotidi za liječenje stanja povezanih s aktivnošću sting kao što je rak - Google Patents
Ciklični dinukleotidi za liječenje stanja povezanih s aktivnošću sting kao što je rakInfo
- Publication number
- HRP20251050T1 HRP20251050T1 HRP20251050TT HRP20251050T HRP20251050T1 HR P20251050 T1 HRP20251050 T1 HR P20251050T1 HR P20251050T T HRP20251050T T HR P20251050TT HR P20251050 T HRP20251050 T HR P20251050T HR P20251050 T1 HRP20251050 T1 HR P20251050T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- compound
- image
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277273P | 2016-01-11 | 2016-01-11 | |
| US201662436759P | 2016-12-20 | 2016-12-20 | |
| EP17704338.7A EP3402801B1 (en) | 2016-01-11 | 2017-01-11 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
| PCT/US2017/013066 WO2017123669A1 (en) | 2016-01-11 | 2017-01-11 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20251050T1 true HRP20251050T1 (hr) | 2025-11-07 |
Family
ID=58010371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20251050TT HRP20251050T1 (hr) | 2016-01-11 | 2017-01-11 | Ciklični dinukleotidi za liječenje stanja povezanih s aktivnošću sting kao što je rak |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10604542B2 (https=) |
| EP (1) | EP3402801B1 (https=) |
| JP (1) | JP6867395B2 (https=) |
| KR (2) | KR102789862B1 (https=) |
| CN (1) | CN109451740B (https=) |
| AU (1) | AU2017207757B2 (https=) |
| BR (1) | BR112018013808A2 (https=) |
| CA (1) | CA3011528A1 (https=) |
| CL (1) | CL2018001870A1 (https=) |
| CO (1) | CO2018008196A2 (https=) |
| DK (1) | DK3402801T3 (https=) |
| EA (1) | EA036421B1 (https=) |
| ES (1) | ES3046957T3 (https=) |
| FI (1) | FI3402801T3 (https=) |
| HR (1) | HRP20251050T1 (https=) |
| HU (1) | HUE073018T2 (https=) |
| IL (1) | IL260427B (https=) |
| LT (1) | LT3402801T (https=) |
| MX (1) | MX2018008266A (https=) |
| MY (1) | MY194058A (https=) |
| PE (1) | PE20181330A1 (https=) |
| PL (1) | PL3402801T3 (https=) |
| PT (1) | PT3402801T (https=) |
| RS (1) | RS67188B1 (https=) |
| SG (1) | SG11201805888SA (https=) |
| SI (1) | SI3402801T1 (https=) |
| SM (1) | SMT202500412T1 (https=) |
| WO (1) | WO2017123669A1 (https=) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA035817B1 (ru) | 2015-03-10 | 2020-08-14 | Адуро Байотек, Инк. | Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона" |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| KR102222186B1 (ko) | 2015-08-13 | 2021-03-03 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
| KR102789862B1 (ko) * | 2016-01-11 | 2025-04-03 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드 |
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| IL264049B2 (en) | 2016-07-06 | 2023-11-01 | Sperovie Biosciences Inc | Compounds, preparations and methods for treating the disease |
| AU2017321609C1 (en) | 2016-08-30 | 2023-11-09 | Dana-Farber Cancer Institute, Inc. | Drug delivery compositions and uses thereof |
| PT3523287T (pt) | 2016-10-04 | 2021-10-06 | Merck Sharp & Dohme | Compostos de benzo[b]tiofeno como agonistas de sting |
| PE20210255A1 (es) | 2016-12-01 | 2021-02-10 | Takeda Pharmaceuticals Co | Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon) |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| KR102702926B1 (ko) | 2017-04-13 | 2024-09-06 | 사이로파 비.브이. | 항-sirp 알파 항체 |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| US11259980B2 (en) | 2017-07-31 | 2022-03-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Soft inflatable exosuit for knee rehabilitation |
| JP2020530838A (ja) | 2017-08-04 | 2020-10-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト |
| RU2020109328A (ru) | 2017-08-04 | 2021-09-06 | Мерк Шарп И Доум Корп. | Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака |
| MX2020002303A (es) | 2017-08-30 | 2020-09-10 | Beijing Xuanyi Pharmasciences Co Ltd | Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon. |
| WO2019046511A1 (en) | 2017-08-31 | 2019-03-07 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE |
| KR102812783B1 (ko) * | 2017-08-31 | 2025-05-26 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
| US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| CN111465610A (zh) * | 2017-09-14 | 2020-07-28 | 詹森生物制药有限公司 | 经修饰核苷亚磷酰胺 |
| US11660311B2 (en) * | 2017-10-10 | 2023-05-30 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| KR20200098511A (ko) | 2017-11-10 | 2020-08-20 | 다케다 야쿠힌 고교 가부시키가이샤 | Sting 조절제 화합물, 및 제조 및 사용 방법 |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3727401A4 (en) | 2017-12-20 | 2022-04-06 | Merck Sharp & Dohme Corp. | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3505527A1 (en) * | 2017-12-29 | 2019-07-03 | Invivogen | Cyclic dinucleotides for cytokine induction |
| US10519187B2 (en) | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| ES2980374T3 (es) * | 2018-03-08 | 2024-10-01 | Bristol Myers Squibb Co | Dinucleótidos cíclicos como agentes anticancerosos |
| WO2019180683A1 (en) | 2018-03-23 | 2019-09-26 | Takeda Pharmaceutical Company Limited | Sting modulator compounds with sulfamate linkages, and methods of making and using |
| EP3774765A4 (en) | 2018-04-03 | 2021-12-29 | Merck Sharp & Dohme Corp. | Aza-benzothiophene compounds as sting agonists |
| JP7326319B2 (ja) | 2018-04-03 | 2023-08-15 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｓｔｉｎｇアゴニストとしてのベンゾチオフェン類及び関連する化合物 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| JP7570235B2 (ja) | 2018-05-25 | 2024-10-21 | インサイト・コーポレイション | Ｓｔｉｎｇ活性化剤としての三環式複素環式化合物 |
| WO2020014127A1 (en) | 2018-07-10 | 2020-01-16 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| TW202030199A (zh) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | 作為ｓｔｉｎｇ促效劑之環狀二核苷酸 |
| US11008344B2 (en) | 2018-07-31 | 2021-05-18 | Incyte Corporation | Tricyclic heteroaryl compounds as STING activators |
| WO2020028566A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| US11691990B2 (en) | 2018-08-16 | 2023-07-04 | Eisai R&D Management Co., Ltd | Salts of compounds and crystals thereof |
| EP3848054B1 (en) | 2018-09-06 | 2025-01-29 | Daiichi Sankyo Company, Limited | Antibody-drug conjugates of cyclic dinucleotide derivatives |
| MX2021002764A (es) | 2018-09-12 | 2021-05-12 | Silverback Therapeutics Inc | Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores. |
| CN110938104B (zh) | 2018-09-21 | 2024-07-12 | 上海迪诺医药科技有限公司 | 环状二核苷酸类似物、其药物组合物及应用 |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| WO2020092127A1 (en) | 2018-10-29 | 2020-05-07 | Venenum Biodesign, LLC | Novel sting agonists |
| WO2020089815A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Antibody conjugates comprising sting agonist |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| US12269840B2 (en) * | 2018-12-04 | 2025-04-08 | Bristol-Myers Squibb Company | Process for the preparation of a cyclic dinucleotide |
| WO2020146237A1 (en) | 2019-01-07 | 2020-07-16 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| CN113423713A (zh) * | 2019-02-05 | 2021-09-21 | 百时美施贵宝公司 | 1,2,5-三-o-苯甲酰基-3-二苄基氨基-3-脱氧核糖作为生产3′-氨基-3′-脱氧腺苷和3′-氨基-3′-脱氧鸟苷的中间体及其受保护的衍生物的合成 |
| IL287938B2 (en) | 2019-05-10 | 2025-07-01 | Takeda Pharmaceuticals Co | Antibody-drug conjugates |
| WO2021007160A1 (en) | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| US12435104B2 (en) * | 2019-07-25 | 2025-10-07 | Beigene, Ltd. | Cyclic dinucleotides as sting agonists |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| EP4082579A4 (en) | 2019-12-26 | 2024-06-26 | National University Corporation Tokai National Higher Education and Research System | POLYNUCLEOTIDE AND MEDICINAL COMPOSITION |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| IL296124A (en) | 2020-03-06 | 2022-11-01 | Daiichi Sankyo Co Ltd | Antibody-drug conjugate including novel cyclic dinucleotide derivative |
| TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
| US20230158057A1 (en) * | 2020-04-21 | 2023-05-25 | Duke University | Compositions and methods for the treatment of pain |
| AU2021270347A1 (en) | 2020-05-11 | 2022-12-15 | Erytech Pharma | Red cell extracellular vesicles (RCEVs) containing cargoes and methods of use and production thereof |
| JP2023532304A (ja) | 2020-07-01 | 2023-07-27 | エーアールエス ファーマシューティカルズ オペレーションズ，インク． | 抗ａｓｇｒ１抗体コンジュゲートおよびその使用 |
| CN116056765A (zh) | 2020-08-07 | 2023-05-02 | 坦伯公司 | 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途 |
| WO2022050300A1 (ja) | 2020-09-02 | 2022-03-10 | 第一三共株式会社 | 新規エンド－β－Ｎ－アセチルグルコサミニダーゼ |
| JP2023545466A (ja) * | 2020-10-15 | 2023-10-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 免疫応答を調節することができる、金属イオンと会合したｓｔｉｎｇアゴニストの結晶多形体 |
| KR102466750B1 (ko) | 2020-10-23 | 2022-11-15 | 아주대학교산학협력단 | 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물 |
| JP2023548310A (ja) | 2020-10-30 | 2023-11-16 | アバクタ・ライフ・サイエンシーズ・リミテッド | Ｆａｐ活性化血清半減期延長型治療用コンジュゲート |
| IL302390A (en) | 2020-11-09 | 2023-06-01 | Takeda Pharmaceuticals Co | Drug antibody conjugates |
| AU2022302611A1 (en) | 2021-06-30 | 2024-02-15 | Kyowa Kirin Co., Ltd. | Polynucleotide and medicinal composition |
| CN118804983A (zh) | 2022-03-02 | 2024-10-18 | 第一三共株式会社 | 含Fc分子的制造方法 |
| KR20250054799A (ko) | 2022-08-29 | 2025-04-23 | 다이이찌 산쿄 가부시키가이샤 | 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트 |
| WO2026027944A1 (en) | 2024-07-30 | 2026-02-05 | Sairopa B.V. | Anti-sirp alpha antibody formulations and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| CA2490626A1 (en) | 2002-06-20 | 2003-12-31 | Nippon Suisan Kaisha, Ltd. | Prodrug, medicinal utilization thereof and process for producing the same |
| WO2005089777A1 (en) * | 2004-03-15 | 2005-09-29 | Karaolis David K R | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| HK1203971A1 (en) * | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| EP2858722B8 (en) | 2012-06-08 | 2018-02-21 | Aduro BioTech, Inc. | Compostions and methods for cancer immunotherapy |
| US9695212B2 (en) | 2012-12-13 | 2017-07-04 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| US9840533B2 (en) | 2013-04-29 | 2017-12-12 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| CA2927009C (en) | 2013-10-21 | 2019-04-23 | Drexel University | Use of sting agonists to treat chronic hepatitis b virus infection |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| WO2015077534A1 (en) | 2013-11-22 | 2015-05-28 | Massachusetts Institute Of Technology | Photovoltaic power balancing and differential power processing |
| US9315523B2 (en) | 2013-12-06 | 2016-04-19 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
| CR20160564A (es) | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| WO2016096577A1 (en) | 2014-12-16 | 2016-06-23 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| EP3546473B1 (en) | 2014-12-16 | 2025-12-10 | Kayla Therapeutics | Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EA035817B1 (ru) | 2015-03-10 | 2020-08-14 | Адуро Байотек, Инк. | Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона" |
| KR102222186B1 (ko) | 2015-08-13 | 2021-03-03 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
| CN107849084B (zh) | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
| KR102789862B1 (ko) * | 2016-01-11 | 2025-04-03 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드 |
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
-
2017
- 2017-01-11 KR KR1020187022863A patent/KR102789862B1/ko active Active
- 2017-01-11 DK DK17704338.7T patent/DK3402801T3/da active
- 2017-01-11 MY MYPI2018702369A patent/MY194058A/en unknown
- 2017-01-11 LT LTEPPCT/US2017/013066T patent/LT3402801T/lt unknown
- 2017-01-11 PL PL17704338.7T patent/PL3402801T3/pl unknown
- 2017-01-11 SG SG11201805888SA patent/SG11201805888SA/en unknown
- 2017-01-11 MX MX2018008266A patent/MX2018008266A/es unknown
- 2017-01-11 EP EP17704338.7A patent/EP3402801B1/en active Active
- 2017-01-11 CN CN201780015198.2A patent/CN109451740B/zh active Active
- 2017-01-11 ES ES17704338T patent/ES3046957T3/es active Active
- 2017-01-11 RS RS20250892A patent/RS67188B1/sr unknown
- 2017-01-11 JP JP2018536116A patent/JP6867395B2/ja active Active
- 2017-01-11 BR BR112018013808-8A patent/BR112018013808A2/pt active Search and Examination
- 2017-01-11 PE PE2018001267A patent/PE20181330A1/es unknown
- 2017-01-11 US US15/748,685 patent/US10604542B2/en active Active
- 2017-01-11 SM SM20250412T patent/SMT202500412T1/it unknown
- 2017-01-11 EA EA201891565A patent/EA036421B1/ru not_active IP Right Cessation
- 2017-01-11 PT PT177043387T patent/PT3402801T/pt unknown
- 2017-01-11 HU HUE17704338A patent/HUE073018T2/hu unknown
- 2017-01-11 AU AU2017207757A patent/AU2017207757B2/en active Active
- 2017-01-11 CA CA3011528A patent/CA3011528A1/en active Pending
- 2017-01-11 WO PCT/US2017/013066 patent/WO2017123669A1/en not_active Ceased
- 2017-01-11 FI FIEP17704338.7T patent/FI3402801T3/fi active
- 2017-01-11 SI SI201731621T patent/SI3402801T1/sl unknown
- 2017-01-11 HR HRP20251050TT patent/HRP20251050T1/hr unknown
- 2017-01-11 KR KR1020257010190A patent/KR20250049441A/ko active Pending
-
2018
- 2018-07-04 IL IL260427A patent/IL260427B/en active IP Right Grant
- 2018-07-10 CL CL2018001870A patent/CL2018001870A1/es unknown
- 2018-08-02 CO CONC2018/0008196A patent/CO2018008196A2/es unknown
-
2020
- 2020-01-31 US US16/778,281 patent/US10961270B2/en active Active
-
2021
- 2021-01-28 US US17/160,578 patent/US11505571B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20251050T1 (hr) | Ciklični dinukleotidi za liječenje stanja povezanih s aktivnošću sting kao što je rak | |
| Stoeck et al. | Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma | |
| Kienast et al. | Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy | |
| Pedersen et al. | Sym004: a novel synergistic anti–epidermal growth factor receptor antibody mixture with superior anticancer efficacy | |
| Lin et al. | Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer | |
| Michel et al. | Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma | |
| Hussain et al. | A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma | |
| RU2014138420A (ru) | Антитела против sez6 и способы их применения | |
| RU2014138474A (ru) | Новые модуляторы и способы применения | |
| RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
| RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
| JP2019506403A5 (https=) | ||
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| JP2017533912A5 (https=) | ||
| RU2018101314A (ru) | Комбинированные способы лечения антагонистами pd-l1 | |
| RU2016122654A (ru) | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка | |
| RU2014128513A (ru) | Раковый маркер и терапевтическая мишень | |
| JP2016520082A5 (https=) | ||
| RU2016147206A (ru) | Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака | |
| JP2016540042A5 (https=) | ||
| IL292658A (en) | Immune modulation with tlr9 agonists for cancer treatment | |
| MX2018012457A (es) | Terapia combinatoria con inhibidores notch y cdk4/6. | |
| RU2018102963A (ru) | Производные анилинпиримидина и их применения | |
| JP2017534574A (ja) | チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法 | |
| SG11202101792TA (en) | Use of tumor inflitrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody |